AegleStem Therapeutics

Aegle Therapeutics is a clinical-stage biotechnology company pioneering the development of first-in-class extracellular vesicle (exosome) therapies for severe dermatological and orphan diseases. The company's lead product candidate, AGLE-102, is an exosome-based therapy derived from mesenchymal stem cells designed to deliver proteins, siRNA, and mRNA to promote tissue regeneration and reduce inflammation. Aegle is currently focused on treating dystrophic epidermolysis bullosa (DEB), a rare and devastating genetic skin blistering disorder, as well as other complex wounds and burn injuries. By leveraging the regenerative properties of stem cell-derived exosomes, the company aims to provide a safer and more efficient alternative to traditional cell-based therapies.